Indeed, clinical trials with atacicept, a recombinant fusion protein that suppresses B cell function and proliferation, blocking BAFF and APRIL, increased disease activity in MS, demonstrating that some B cell subsets may have anti-inflammatory functions [24]. Here, TNFSF13 is linked to myeloid sarcoma.